Atherogenics Inc (AGIX)

Atherogenics Inc is related to 5 other symbols. To date we've encountered 101 releases involving Atherogenics Inc.

Last Price: 0.38 (0.00) - 9/5/2008, 4:00pm

• Open: N/A
• High: N/A
• Low: N/A

Atherogenics Inc Options

• Atherogenics Inc "Business Partners"
• Atherogenics Inc Press Releases
• Atherogenics Inc News
• Atherogenics Inc Contact
• Atherogenics Inc Related (via TRYNT)

Atherogenics Inc "Business Partners"

A "business partner" is defined as a third party company that has co-released at least one press release with Atherogenics Inc.

• IMGG
• MIOK
• NCII
• TIE
• WEW

^

Atherogenics Inc Press Releases

• AtheroGenics: AtheroGenics Reports Third Quarter 2006 Financial Results (Trackbacks) (Backlinks), Tue, 24 Oct 2006 4:00:00 PDT

  ATLANTA, GA (MARKET WIRE) AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today reported financial results for the third quarter and nine months ended September 30, 2006.

• AtheroGenics: AtheroGenics to Webcast Third Quarter Results Conference Call on October 24, 2006 (Trackbacks) (Backlinks), Thu, 12 Oct 2006 4:00:00 PDT

  ATLANTA, GA (MARKET WIRE) AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it expects to release its third quarter 2006 results of operations on Tuesday, October 24, 2006, before the U.S. financial markets open.

• AtheroGenics: AtheroGenics to Present at the A.G. Edwards Emerging Growth Conference on September 20, 2006 (Trackbacks) (Backlinks), Thu, 14 Sep 2006 5:00:00 PDT

  ATLANTA, GA (MARKET WIRE) AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced today that Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present a company overview and update at the A.G. Edwards Emerging Growth Conference on Wednesday, September 20, 2006, at 8:30 a.m. ET at The New York Palace Hotel in New York, NY.

• AtheroGenics, Inc.: AtheroGenics to Present at Thomas Weisel Partners' Healthcare Conference on September 6, 2006 (Trackbacks) (Backlinks), Tue, 29 Aug 2006 5:14:00 PDT

  ATLANTA, GA (MARKET WIRE) AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced today that Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present a company overview and update at the Thomas Weisel Partners Healthcare Conference on Wednesday, September 6, 2006, at 1:30 p.m. EDT at The Four Seasons Hotel in Boston, Massachusetts.

• AtheroGenics, Inc.: AtheroGenics, Inc. Announces Two New Board Members (Trackbacks) (Backlinks), Tue, 18 Jul 2006 7:44:00 PDT

  ATLANTA, GA (MARKET WIRE) AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced the election of two new members to its Board of Directors: Sam L. Barker, Ph.D., a founder of Clearview Projects, Inc. and former pharmaceutical industry executive at Bristol-Myers Squibb; and Margaret E. Grayson, President of AEP Government Solutions Group and

• AtheroGenics, Inc.: AtheroGenics to Webcast Second Quarter Results Conference Call on July 20, 2006 (Trackbacks) (Backlinks), Thu, 6 Jul 2006 12:11:00 PDT

  ATLANTA, GA (MARKET WIRE) AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it expects to release its second quarter 2006 results of operations on Thursday, July 20, 2006, before the U.S. financial markets open.

• AtheroGenics: AtheroGenics Announces Promotion of Joseph M. Gaynor, Jr. to Senior Vice President (Trackbacks) (Backlinks), Thu, 6 Jul 2006 6:41:00 PDT

  ATLANTA, GA (MARKET WIRE) AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced the promotion of Joseph M. Gaynor, Jr. to Senior Vice President and General Counsel.

• AtheroGenics: AtheroGenics to Present at Needham & Company's Fifth Annual Biotechnology and Medical Technology Conference on June 14, 2006 (Trackbacks) (Backlinks), Thu, 8 Jun 2006 7:45:00 PDT

  ATLANTA, GA (MARKET WIRE) AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced today that Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer, is scheduled to present a company overview and update at the Needham & Company Fifth Annual Biotechnology and Medical Technology Conference on Wednesday, June 14, 2006, at 4:30 p.m. EDT at The

• AtheroGenics: AtheroGenics Announces Promotions of Three Senior Executives (Trackbacks) (Backlinks), Thu, 11 May 2006 6:45:00 PDT

  ATLANTA, GA (MARKET WIRE) AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced the promotion of Mark P. Colonnese to Executive Vice President, Commercial Operations; Rob Scott, M.D. to Executive Vice President, Research and Development; and W. Charles Montgomery, Ph.D. to Senior Vice President, Business Development and Alliance Management. Mr.

• AtheroGenics: AtheroGenics to Present at Morgan Stanley Global Healthcare Unplugged Conference on May 3, 2006 (Trackbacks) (Backlinks), Fri, 28 Apr 2006 6:31:00 PDT

  ATLANTA, GA (MARKET WIRE) AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, announced today that Russell M. Medford, M.D., Ph.D., President and Chief Executive Officer, and Rob Scott, M.D., Senior Vice President, Clinical Development and Regulatory Affairs and Chief Medical Officer, are scheduled to present a company overview and update at the Morgan Stanley

^

Atherogenics Inc News

• Movers roundup: Pepsi Bottling, AtheroGenics (AP), Tue, 2 Sep 2008 22:55:41 Etc/GMT
• AtheroGenics shares fall after payment default (AP), Tue, 2 Sep 2008 21:16:59 Etc/GMT
• AtheroGenics Bills Unpaid (Zacks.com), Tue, 2 Sep 2008 17:31:32 Etc/GMT
• ATHEROGENICS INC Files SEC form 8-K, Triggering Events That Accelerate or Increase a Direct Financial Obligation or a (EDGAR Online), Tue, 2 Sep 2008 14:39:06 Etc/GMT
• UPDATE - AtheroGenics to not repay 2008 notes (at Reuters), Tue, 2 Sep 2008 13:53:18 Etc/GMT
• AtheroGenics Seeks to Realign Capital Structure (Marketwire), Tue, 2 Sep 2008 12:39:00 Etc/GMT
• ATHEROGENICS INC Financials (EDGAR Online Financials), Wed, 20 Aug 2008 13:04:18 Etc/GMT
• Why We Love Wild Penny Stocks (at Motley Fool), Thu, 14 Aug 2008 17:21:18 Etc/GMT
• ATHEROGENICS INC Files SEC form 10-Q, Quarterly Report (EDGAR Online), Mon, 11 Aug 2008 21:21:11 Etc/GMT
• New Star Analyst Rankings for ATHEROGENICS INC (StarMine), Wed, 6 Aug 2008 13:22:12 Etc/GMT
• AtheroGenics records $14M second-quarter deficit (at bizjournals.com), Tue, 5 Aug 2008 14:15:10 Etc/GMT
• AtheroGenics Second Quarter 2008 Earnings Call scheduled for 9:00 am ET today (Vcall), Tue, 5 Aug 2008 13:00:00 Etc/GMT
• ATHEROGENICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (EDGAR Online), Tue, 5 Aug 2008 12:47:44 Etc/GMT
• Q2 2008 AtheroGenics, Inc. Earnings Release - Before Market Open (CCBN), Tue, 5 Aug 2008 11:07:15 Etc/GMT
• AtheroGenics Reports Second Quarter 2008 Financial Results (Marketwire), Tue, 5 Aug 2008 11:00:00 Etc/GMT
• ATHEROGENICS INC Files SEC form 8-K, Other Events (EDGAR Online), Thu, 31 Jul 2008 13:24:20 Etc/GMT
• AtheroGenics Reports Positive Results From ANDES Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes (Marketwire), Thu, 31 Jul 2008 11:00:00 Etc/GMT
• AtheroGenics to Report Second Quarter 2008 Financial Results on August 5, 2008 (Marketwire), Fri, 25 Jul 2008 11:15:00 Etc/GMT
• ATHEROGENICS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; (EDGAR Online), Mon, 30 Jun 2008 13:33:27 Etc/GMT
• AtheroGenics Receives Notice of Non-Compliance With Listing Requirement for the NASDAQ Global Market (Marketwire), Mon, 30 Jun 2008 13:21:00 Etc/GMT

^

Atherogenics Inc Contact

• Corporate Communications
  Donna L. Glasky
  AtheroGenics, Inc.
  678-336-2517
  Email Contact
  
  Media Relations
  Jayme Maniatis
  Vice President
  Schwartz Communications, Inc.
  781-684-0770
  Email Contact
  
  

TRYNT Related

• Atherogenics (AGIX.MX)
• Lehman Yeelds Agix (LBHYI.PK)

^

What is a Stock Cloud?

A Stock Cloud is a tag cloud like display of stock ticker symbols. The larger the ticker symbol the more frequent that company distributes press releases.